LAMIVUDINE


Trade Names	EPIVIR EPIVIR-HBV LAMIVUDINE
Synonyms	BCH 189, (-)- Epivir Epivir-hbv GR 109714X GR-109714X Lamivudine Lamivudine teva Lamivudinum NSC-760061 Virolam Zeffix
Status
Molecule Category	Free-form
ATC	J05AF05
UNII	2T8Q726O95
EPA CompTox	DTXSID7023194


InChI Key	JTEGQNOMFQHVDC-NKWVEPMBSA-N
Smiles	Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1
InChI	InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

Property Name	Value
Molecular Formula	C8H11N3O3S
Molecular Weight	229.26
AlogP	-0.59
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	2.0
Polar Surface Area	90.37
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	15.0

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	DailyMed
DNA inhibitor	INHIBITOR	DailyMed
DNA inhibitor	INHIBITOR	DailyMed
DNA polymerase/reverse transcriptase inhibitor	INHIBITOR	DailyMed
Human immunodeficiency virus type 1 reverse transcriptase inhibitor	INHIBITOR	DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	42	-	-	-	-
Structural protein	370	-	-	-	17.73-94.31

	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Anas sp.	-	100	-	-	96
Duck hepatitis B virus	40-40	-	-	-	52.7-96
HBV genotype D	30-460	-	-	-	-
Hepatitis B virus	3.8-640	25-600	-	-	0.81-118.45
Homo sapiens	8-400	2-610	-	-	16-99.96
Human T-lymphotropic virus 1	-	-	-	-	100
Human immunodeficiency virus	1.8-210	-	-	-	-
Human immunodeficiency virus 1	1.8-969	21.8-812	-	-	37-100
Human immunodeficiency virus type 1	21	-	-	-	-
Human immunodeficiency virus type 2 (ISOLATE ROD)	180	-	-	-	-
Mycobacterium avium	-	-	-	-	0
Mycobacterium bovis BCG	-	-	-	-	0
Mycobacterium tuberculosis	-	-	-	-	0
epsteinBarr virus	400	-	-	-	-

Header

Compound Name

Maximum Phase

Compound Structure

Smile

Inchi

InchiKey

Compound Properties

Molecular Formula

Molecular Weight

ALogP

PSA

Countries
South Africa
USA

Resources	Reference
CAS NUMBER	134678-17-4
ChEBI	63577
ChEMBL	CHEMBL141
DrugBank	DB00709
DrugCentral	1539
FDA SRS	2T8Q726O95
Human Metabolome Database	HMDB0014847
KEGG	C07065
PDB	3TC
PharmGKB	PA450163
PubChem	60825
SureChEMBL	SCHEMBL109675
ZINC	ZINC000000012346

EcoDrug+ was developed under the PREMIER Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information EcoDrug+ contains.

Elements of EcoDrug+ were developed under the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT Center for Science Ltd is thanked for providing computational resources. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

Content of EcoDrug+ is provided without guarantee for correctness.

Cite Us:

Ashenafi Legehar, Siobhán Monaghan, Mael Briand, Akseli Niemelä, Leo Ghemtio, Ziaurrehman Tanoli, A Ross Brown, Charles R Tyler, Henri Xhaard, EcoDrug PLUS: an advanced database for drug target conservation analysis and environmental risk assessment, Nucleic Acids Research, Volume 54, Issue D1, 6 January 2026, Pages D1397–D1404, https://doi.org/10.1093/nar/gkaf1251

This work is licensed under Creative Commons Attribution-ShareAlike 4.0 International License

Last update: Monday, 23^rd March 2026

LAMIVUDINE

Structure

Physicochemical Descriptors

Pharmacology

Related Entries

Environmental Exposure

Cross References